MTOR and myeloproliferative disorder: Of note, our results suggest that the PI3K/AKT/mTOR signaling serves as a driver of mitochondrial abnormalities in MPN platelets, as the inhibition of mitochondrial activities by α-KG supplementation decreased pathway activation.